Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05717686
Other study ID # AB-10-8001
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date February 28, 2023
Est. completion date January 31, 2025

Study information

Verified date March 2024
Source AusperBio Therapeutics Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of AHB-137 subcutaneous injection in healthy volunteers and in chronic hepatitis B (CHB) patients after single and multiple doses. In addition, the study will evaluate the initial antiviral efficacy of AHB-137 in CHB patients following a multiple dosing regimen.


Description:

This is a first-in-human study of AHB-137, consisting of four parts. Parts A and B are randomized, double-blinded, placebo-controlled studies designed to assess the safety, tolerability, pharmacokinetics of AHB-137 following subcutaneous injection in healthy volunteers at a 6:2 ratio of AHB-137 to placebo. Part A is a single-ascending dose (SAD) study, and Part B is a single-ascending dose (SAD) study, and Part B is a multiple dose (MD) study. Part C is an open label MD study with up to 6 CHB patients. Part D is a double blinded study in CHB patients at a 4:1 ratio to receive AHB-137 or placebo. Study advancement to subsequent parts/cohorts will require satisfactory interim reviews of available cumulative safety data by the Safety Review Committees (SRC), using the safety criteria and review procedures described in the protocol.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 90
Est. completion date January 31, 2025
Est. primary completion date August 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Healthy participants are required to meet all the following inclusion criteria in order to be enrolled in the study: 1. 18-65 years old male or female. 2. Body Mass Index (BMI) between 19 to 35 kg/m2 (inclusive) and body weight equal to or over 45 kg. 3. Participants' COVID-19 PCR test should be negative during screening. 4. Participants' COVID-19 Rapid Antigen Test (RAT) should be negative at check-in. - CHB patients are required to meet all the following inclusion criteria in order to be enrolled in the study: 1. Have given written informed consent (signed and dated) and any authorizations required by local law and is able to comply with all study requirements. 2. Age 18 to 65 years old. 3. ALT = 5 ULN for CHB patients recruited to Part C; ALT = 2 ULN for CHB patients recruited to Part D. 4. CHB patients who have documented chronic HBV infection equal to or above 6 months prior to screening. Otherwise, CHB patients need to be HBsAg positive and IgM HBcAb negative. 5. CHB patients participating in Part D should have been on commercially available HBV OAV treatment(s) for at least 6 months with no change in regimen for 3 months prior to screening. HBV DNA under limit of quantification (LOQ) at Screening. 6. Both HBeAg positive and negative CHB patients can be recruited to Part C of the study. Only HBeAg negative CHB patients can be recruited to Part D of the study. 7. COVID-19 RAT test should be negative at check-in. Exclusion Criteria: - Healthy participants are required to not meet any of the following exclusion criteria in order to be enrolled in the study: 1. Pregnant (positive pregnancy test) or lactating women. Male participants without using proper contraceptives (e.g. condom) with partners who are pregnant or lactating. 2. History or symptoms of any clinically significant gastrointestinal, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardio-vascular, endocrinological, hematological or allergic disease, metabolic disorder, cancer or cirrhosis. 3. Personal history of congenital long QT syndrome or family history of sudden cardiac death. 4. Any confirmed significant allergic reactions (urticaria or anaphylaxis) against any drug, or multiple drug allergies (non-active hay fever is acceptable). 5. Any clinically significant concomitant diseases or condition that could interfere with, or treatment of which might interfere with, the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the participant in this study. 6. Clinically relevant electrocardiogram (ECG) abnormalities on screening ECG. 7. ECG with QRS and/or T-wave judged to be unfavorable for a consistently accurate QT measurement. 8. Creatinine clearance (CrCl) cutoff = 60 ml/min (using the Cockcroft-Gault formula). 9. Positive test at screening of any of the following: hepatitis A (HAV IgM Ab), hepatitis B (HBsAg), hepatitis C (HCV RNA or HCV Ab), human immunodeficiency virus 1 and 2 (HIV Ab), or TP-Ab. 10. Any other clinically significant abnormalities in laboratory test results at screening. In the case of uncertain or questionable results, tests performed during screening may be repeated before randomization to confirm eligibility. 11. History of bleeding diathesis or coagulopathy. CHB patients are required to not meet any of the following exclusion criteria in order to be enrolled in the study: 1. History of liver cirrhosis and/or evidence of cirrhosis as determined by any 1 of the following: 1. Liver biopsy (i.e., Metavir Score F4) within 2 years of screening, or 2. FibroScan > 12 KPa, within 12 months of screening, or 3. AST-to-Platelet Index (APRI) > 2 and FibroSure result > 0.7 within 12 months of screening. For patients without a test for cirrhosis in the above timeframes, FibroScan, or APRI and FibroSure, may be performed during the screening period to rule out cirrhosis History of liver failure as evidenced by ascites, hepatic encephalopathy, and/or gastric or esophageal varices. 2. History of liver disease other than hepatitis B. 3. Co-infection with TP, HCV, HIV, or hepatitis D virus (HDV). 4. Body mass index >35 kg/m2 . 5. History or suspected presence of vasculitis . 6. Diagnosed hepatocellular carcinoma or suspected hepatocellular carcinoma as evidenced by screening alpha-fetoprotein =200 ng/mL. If the screening alpha-fetoprotein is =50 ng/mL and <200 ng/mL, the absence of liver mass must be documented by imaging within 6 months before randomization. 7. Clinically relevant electrocardiogram (ECG) abnormalities on screening ECG. 8. Screening laboratory results as follows, or any other clinically significant abnormalities in screening laboratory values that would render a patient unsuitable for inclusion. 1. ALT > 5 x ULN for Part C or > 2 x ULN for Part D 2. Total bilirubin > 1.25 x ULN 3. Serum albumin < 3.4 g/dL 4. International normalized ratio of prothrombin time > 1.25 5. Platelet count <140 x 10^9/L 6. Hemoglobin <12.0 g/dL for males and <11.0 g/dL for females 7. White blood cell count <3.0 k/mm3 8. Serum creatinine >1.1 x ULN 9. Urine protein/creatinine ratio =0.2 mg/mg. In the event of a ratio above this threshold, eligibility may be confirmed by a quantitative total urine protein measurement of <150 mg/24 hour 10. Positive test (including trace) for blood on urinalysis. In the event of a positive test, eligibility may be confirmed with urine microscopy showing <5 red blood cells per high power field 9. Clinically significant abnormalities and/or poorly controlled medical conditions (e.g. Cardiovascular, pulmonary, metabolic disease) in the opinion of the investigator. 10. History of bleeding diathesis or coagulopathy. 11. History of extrahepatic disorders possibly related to HBV immune complexes (e.g., glomerulonephritis, polyarteritis nodosa) . 12. Active infection other than HBV, requiring systemic antiviral or antimicrobial therapy that will not be completed prior to Study Day 1.

Study Design


Intervention

Drug:
AHB-137 injection
AHB-137 will be administered
Placebo
Placebo will be administered

Locations

Country Name City State
Hong Kong Queen Mary Hospital Hong Kong
New Zealand New Zealand Clinical Research Grafton Auckland
Taiwan Chia-Yi Christian Hospital Chiayi City
Taiwan E-DA Hospital Kaohsiung
Taiwan Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung
United States University of Maryland Baltimore Baltimore Maryland
United States American Research Corporation Houston Texas
United States NYU Langone Health New York New York
United States Stanford Medicine Redwood City California

Sponsors (1)

Lead Sponsor Collaborator
AusperBio Therapeutics Inc.

Countries where clinical trial is conducted

United States,  Hong Kong,  New Zealand,  Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of Participants With Treatment-Emergent Adverse Events (TEAEs) in Healthy Volunteers Up to 30 days for SAD, up to 113 days for MD
Primary Proportion of Participants With Treatment-Emergent Adverse Events (TEAEs) in CHB patients Up to 204 days for MD
Secondary The anti-HBV efficacy of AHB-137: evaluate the change in serum HBsAg (log10 IU/mL) from baseline. Up to 204 days
Secondary The anti-HBV efficacy of AHB-137: evaluate the expression of HBsAb in serum. Up to 204 days
Secondary The pharmacokinetic profile of AHB-137: the maximum observed plasma concentration (Cmax) of AHB-137 Up to 30 days for SAD; up to 204 days for MD
Secondary The pharmacokinetic profile of AHB-137: time of observed maximal concentration (Tmax) of AHB-137 Up to 30 days for SAD; up to 204 days for MD
Secondary The pharmacokinetic profile of AHB-137: areas under the concentration time curve (AUC) of AHB-137 Up to 30 days for SAD; up to 204 days for MD
Secondary The pharmacokinetic profile of AHB-137: mean residence time (MRT) of AHB-137 Up to 30 days for SAD; up to 204 days for MD
Secondary The pharmacokinetic profile of AHB-137: terminal half-life (t1/2) of AHB-137 Up to 30 days for SAD; up to 204 days for MD
Secondary The pharmacokinetic profile of AHB-137: apparent subcutaneous plasma clearance (CL/F) of AHB-137 Up to 30 days for SAD; up to 204 days for MD
Secondary The pharmacokinetic profile of AHB-137: amount of AHB-137 excreted in urine (Ae) Day 1-4 for SAD; Day 1-4 and Day 22-25 for MD
Secondary The pharmacokinetic profile of AHB-137: renal clearance (CLr) of AHB-137 Day 1-4 for SAD; Day 1-4 and Day 22-25 for MD
See also
  Status Clinical Trial Phase
Recruiting NCT04496882 - Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue Phase 4
Completed NCT04083716 - A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults Phase 1
Not yet recruiting NCT03038802 - A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection Phase 1/Phase 2
Completed NCT05310487 - Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects Phase 1
Recruiting NCT06070051 - Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy Phase 1
Terminated NCT05001022 - A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects Phase 1
Recruiting NCT04139850 - The Establishment of Korean Hepatitis B Patients Cohort
Recruiting NCT05343481 - Efficacy of VTP-300 in Chronic Hepatitis B Infection Phase 2
Not yet recruiting NCT05490836 - Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients N/A
Recruiting NCT04543565 - Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study Phase 3
Active, not recruiting NCT02894918 - A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs Phase 4
Not yet recruiting NCT02793791 - Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients N/A
Recruiting NCT02287857 - Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B N/A
Recruiting NCT01965418 - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Phase 4
Recruiting NCT01491295 - Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Phase 4
Terminated NCT01872988 - Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma Phase 3
Recruiting NCT01487876 - Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients Phase 2
Completed NCT01531166 - A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon N/A
Not yet recruiting NCT01436539 - Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Phase 4
Recruiting NCT01360879 - Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease N/A